These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

292 related items for PubMed ID: 21332366

  • 1. Targeting integrins in hepatocellular carcinoma.
    Wu Y, Qiao X, Qiao S, Yu L.
    Expert Opin Ther Targets; 2011 Apr; 15(4):421-37. PubMed ID: 21332366
    [Abstract] [Full Text] [Related]

  • 2. Targeted therapy of hepatocellular cancer.
    Wysocki PJ.
    Expert Opin Investig Drugs; 2010 Feb; 19(2):265-74. PubMed ID: 20074016
    [Abstract] [Full Text] [Related]

  • 3. Emerging targeted strategies in advanced hepatocellular carcinoma.
    Finn RS.
    Semin Liver Dis; 2013 Feb; 33 Suppl 1():S11-9. PubMed ID: 23457035
    [Abstract] [Full Text] [Related]

  • 4. Laminin alpha 5 mediates ectopic adhesion of hepatocellular carcinoma through integrins and/or Lutheran/basal cell adhesion molecule.
    Kikkawa Y, Sudo R, Kon J, Mizuguchi T, Nomizu M, Hirata K, Mitaka T.
    Exp Cell Res; 2008 Aug 15; 314(14):2579-90. PubMed ID: 18635166
    [Abstract] [Full Text] [Related]

  • 5. Integrins as differential cell lineage markers of primary liver tumors.
    Volpes R, van den Oord JJ, Desmet VJ.
    Am J Pathol; 1993 May 15; 142(5):1483-92. PubMed ID: 7684197
    [Abstract] [Full Text] [Related]

  • 6. Novel therapeutic targets and predictive markers for hepatocellular carcinoma.
    Chan SL, Chan AW, Yeo W.
    Expert Opin Ther Targets; 2015 Jul 15; 19(7):973-83. PubMed ID: 25910512
    [Abstract] [Full Text] [Related]

  • 7. Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma.
    Kudo M.
    Dig Dis; 2011 Jul 15; 29(3):289-302. PubMed ID: 21829020
    [Abstract] [Full Text] [Related]

  • 8. [Hepatocellular carcinoma].
    Kondo S, Ueno H, Morizane C, Okusaka T.
    Gan To Kagaku Ryoho; 2010 Jul 15; 37(7):1219-23. PubMed ID: 20647702
    [Abstract] [Full Text] [Related]

  • 9. Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma.
    Zhu AX.
    Expert Opin Investig Drugs; 2010 May 15; 19(5):663-72. PubMed ID: 20367287
    [Abstract] [Full Text] [Related]

  • 10. Systemic treatment of hepatocellular carcinoma: dawn of a new era?
    Zhu AX.
    Ann Surg Oncol; 2010 May 15; 17(5):1247-56. PubMed ID: 20405329
    [Abstract] [Full Text] [Related]

  • 11. Systemic therapies in hepatocellular carcinoma.
    Wörns MA, Weinmann A, Schuchmann M, Galle PR.
    Dig Dis; 2009 May 15; 27(2):175-88. PubMed ID: 19546557
    [Abstract] [Full Text] [Related]

  • 12. Simvastatin modulates the adhesion and growth of hepatocellular carcinoma cells via decrease of integrin expression and ROCK.
    Relja B, Meder F, Wang M, Blaheta R, Henrich D, Marzi I, Lehnert M.
    Int J Oncol; 2011 Mar 15; 38(3):879-85. PubMed ID: 21206971
    [Abstract] [Full Text] [Related]

  • 13. An update on clinical trials in the treatment of advanced hepatocellular carcinoma.
    Lee JK, Abou-Alfa GK.
    J Clin Gastroenterol; 2013 Jul 15; 47 Suppl():S16-9. PubMed ID: 23751800
    [Abstract] [Full Text] [Related]

  • 14. Prognostic markers and putative therapeutic targets for hepatocellular carcinoma.
    Frau M, Biasi F, Feo F, Pascale RM.
    Mol Aspects Med; 2010 Apr 15; 31(2):179-93. PubMed ID: 20176048
    [Abstract] [Full Text] [Related]

  • 15. Molecularly targeted therapy in hepatocellular carcinoma.
    Huynh H.
    Biochem Pharmacol; 2010 Sep 01; 80(5):550-60. PubMed ID: 20371362
    [Abstract] [Full Text] [Related]

  • 16. Cell-matrix talks: effects on differentiation of hepatocellular carcinoma.
    Wu XZ, Chen D.
    Minerva Gastroenterol Dietol; 2006 Dec 01; 52(4):407-13. PubMed ID: 17108870
    [Abstract] [Full Text] [Related]

  • 17. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
    Pang RW, Poon RT.
    Oncology; 2007 Dec 01; 72 Suppl 1():30-44. PubMed ID: 18087180
    [Abstract] [Full Text] [Related]

  • 18. Characterization of hepatocellular carcinoma cell lines based on cell adhesion molecules.
    Jung CW, Song TJ, Lee KO, Choi SB, Kim WB, Suh SO, Kim YC, Choi SY.
    Int J Mol Med; 2012 Jun 01; 29(6):1158-64. PubMed ID: 22447134
    [Abstract] [Full Text] [Related]

  • 19. Targeting fibroblast growth factor receptor signaling in hepatocellular carcinoma.
    Cheng AL, Shen YC, Zhu AX.
    Oncology; 2011 Jun 01; 81(5-6):372-80. PubMed ID: 22269894
    [Abstract] [Full Text] [Related]

  • 20. Targeted therapy for liver cancer: updated review in 2012.
    Kudo M.
    Curr Cancer Drug Targets; 2012 Nov 01; 12(9):1062-72. PubMed ID: 22920326
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.